Cited by 10Suicide and Self-Harm StudiesTreatment of Major DepressionBipolar Disorder and Treatment

Clinical trials for rapid changes in suicidal ideation: lessons from ketamine

Open access
Ballard, Elizabeth D., Fields, Jessica, Farmer, Cristan A., Zarate, Carlos A.·2021·Suicide and Life-Threatening Behavior

Abstract

Rapid‐acting treatments for suicidal thoughts are critically needed. Consequently, there is a burgeoning literature exploring psychotherapeutic, pharmacologic, or device‐based brief interventions for suicidal thoughts characterized by a rapid onset of action. Not only do these innovative treatments have potentially important clinical benefits to patient populations, they also highlight a number of methodological considerations for suicide research. First, while most clinical trials related to suicide risk focus on suicide attempts, new clinical trials that use suicidal thoughts as the primary outcome require a number of slight modifications to their clinical trial design. Second, the rapid onset of these new interventions permits an experimental therapeutics approach to suicide research, in which psychological and neurobiological markers are embedded into clinical trials to better understand the underlying pathophysiology of suicidal thoughts. The following review discusses these methodological innovations in light of recent research using the N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine, which has been associated with rapid effects on suicidal thoughts. We hope that “lessons learned” from the ketamine literature will provide a blueprint for all researchers evaluating rapid‐acting treatments for suicidal thoughts, whether pharmacologic or psychotherapeutic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/sltb.12663

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Such an approach has the potential to further our understanding of both mechanisms of action for suicide-focused treatments as well as elucidate the neural correlates of suicide risk.

    “Such an approach, which has already been implemented in rapid-acting clinical trials for depression (18), has the potential to further our understanding of both mechanisms of action for suicide-focused treatments as well as elucidate the neural correlates of suicide risk (19).”

    From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [19]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Baldessarini RJ, Tondo L, & Hennen J (1999). Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Journal of Clinical Psychiatry, 60 Suppl, 2, 77– 84; discussion 111–116. 10073392

Cited by

Sorted by citations

Authors
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A.
Affiliations
National Institutes of Health (US)
Corresponding author
Ballard, Elizabeth D.
Venue
Suicide and Life-Threatening Behavior
Publisher
Wiley
Published
2021-02
Volume
51
Issue
1
Pages
27-35
ISSN
  • 0363-0234 (ISSN-L)
  • 1943-278X
OpenAlex
W3132180119
Cited by
10
References
64
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • Suicide and Life-Threatening Behavior (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (IRP‐NIMH‐NIH, ZIAMH002857)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
suicidal ideation, ketamine, NMDA receptor antagonists, clinical trial design, suicide risk, experimental therapeutics, neurobiological markers, psychotherapeutic interventions, pharmacological interventions
MeSH terms
Clinical Trials as Topic, Depression, Humans, Ketamine, Suicide, Attempted, Biomarkers, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review